Bisphosphonates enhance effect of EGFR-TKIs in NSCLC patients with EGFR mutation and bone metastases

被引：0
|
作者：
Jiang, T. [1 ]
Zhou, C. [1 ]
机构：
[1] Tongji Univ, Shanghai Pulm Hosp, Med Oncol, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
基金：
中国国家自然科学基金;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
457P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Bisphosphonates Enhance Effect of EGFR-TKIs in NSCLC Patients with EGFR Mutation and Bone Metastases
    Jiang, Tao
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1236 - S1236
  • [2] Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases
    Guowei Zhang
    Ruirui Cheng
    Zengli Zhang
    Tao Jiang
    Shengxiang Ren
    Zhiyong Ma
    Sha Zhao
    Caicun Zhou
    Jun Zhang
    Scientific Reports, 7
  • [3] Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases
    Zhang, Guowei
    Cheng, Ruirui
    Zhang, Zengli
    Jiang, Tao
    Ren, Shengxiang
    Ma, Zhiyong
    Zhao, Sha
    Zhou, Caicun
    Zhang, Jun
    SCIENTIFIC REPORTS, 2017, 7
  • [4] Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study
    Huang, Chu-ying
    Wang, Li
    Feng, Cheng-jun
    Yu, Ping
    Cai, Xiao-hong
    Yao, Wen-xiu
    Xu, Yong
    Liu, Xiao-ke
    Zhu, Wen-jiang
    Wang, Yan
    Zhou, Jin
    Lu, You
    Wang, Yong-sheng
    ONCOTARGET, 2016, 7 (41): : 66480 - 66490
  • [5] Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
    Wen, Miaomiao
    Xia, Jinghua
    Sun, Ying
    Wang, Xuejiao
    Fu, Xianghui
    Zhang, Yanning
    Zhang, Zhipei
    Zhou, Yongan
    Li, Xiaofei
    BIOLOGICS-TARGETS & THERAPY, 2018, 12 : 183 - 190
  • [6] Tamoxifen Might Enhance the Effect of EGFR-TKIs on EGFR-Mutant NSCLC Cells
    He, Y.
    Zhang, Q.
    Zheng, M.
    Chen, Z.
    Wei, X.
    Yang, X.
    Gao, X.
    Wu, Y.
    Liu, S.
    Zhou, Q.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S242 - S242
  • [7] Impacts of EGFR mutation and EGFR-TKIs on incidence of brain metastases in advanced non-squamous NSCLC
    Wang, Bao-Xiao
    Ou, Wei
    Mao, Xiao-Yong
    Liu, Zui
    Wu, Hui-Qi
    Wang, Si-Yu
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2017, 160 : 96 - 100
  • [8] EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with multiple brain metastases
    Jiang, T.
    Zhou, C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [9] EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases
    Jiang, Tao
    Zhang, Yongchang
    Li, Xuefei
    Zhao, Chao
    Chen, Xiaoxia
    Su, Chunxia
    Ren, Shengxiang
    Yang, Nong
    Zhou, Caicun
    EUROPEAN JOURNAL OF CANCER, 2019, 121 : 98 - 108
  • [10] Association between clinical outcome of first EGFR-TKIs and T790M mutation in NSCLC patients harboring EGFR mutation with acquired resistance to EGFR-TKIs
    Oya, Y.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S622 - S622
12345